MEREO BIOPHARMA GROUP PLC Increase (Decrease) in Prepaid Expense and Other Assets
MEREO BIOPHARMA GROUP PLC (MREO) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$952.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$681.00K.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$271.00K, a 201.12% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$235.00K.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $164.00K.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in prepaid expense and other assets for fiscal 2025 was $84.00K.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$2.98M.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$502.00K.
- MEREO BIOPHARMA GROUP PLC increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$532.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$681.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$952.00K 10-Q · filed 2026-08-11 | -$1.19M derived: sum of 3 quarters · filed 2026-08-11 | -$1.02M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$271.00K 10-Q · filed 2026-05-12 | -$506.00K derived: sum of 2 quarters · filed 2026-05-12 | -$342.00K derived: sum of 3 quarters · filed 2026-05-12 | -$455.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$235.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$71.00K derived: sum of 2 quarters · filed 2026-03-19 | -$184.00K derived: sum of 3 quarters · filed 2026-08-11 | $84.00K 10-K · filed 2026-03-19 |
| 2025-09-30 | $164.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $51.00K derived: sum of 2 quarters · filed 2026-08-11 | $319.00K 10-Q · filed 2025-11-10 | -$1.15M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $155.00K 10-Q · filed 2026-08-11 | -$1.31M derived: sum of 3 quarters · filed 2026-08-11 | -$2.18M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $268.00K 10-Q · filed 2026-05-12 | -$1.20M derived: sum of 2 quarters · filed 2026-05-12 | -$2.07M derived: sum of 3 quarters · filed 2026-05-12 | -$773.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$2.34M derived: sum of 2 quarters · filed 2026-03-19 | -$1.04M derived: sum of 3 quarters · filed 2026-03-19 | -$2.98M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$870.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $425.00K derived: sum of 2 quarters · filed 2025-11-10 | -$1.51M 10-Q · filed 2025-11-10 | $401.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$644.00K 10-Q · filed 2025-08-12 | $1.27M derived: sum of 3 quarters · filed 2025-08-12 | -$7.25M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$1.94M 10-Q · filed 2025-05-13 | -$24.00K derived: sum of 2 quarters · filed 2025-05-13 | -$8.55M derived: sum of 3 quarters · filed 2025-05-13 | $851.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -$6.61M derived: sum of 2 quarters · filed 2025-03-26 | $2.79M derived: sum of 3 quarters · filed 2025-03-26 | -$502.00K 10-K · filed 2025-03-26 |
| 2023-09-30 | -$8.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $875.00K derived: sum of 2 quarters · filed 2024-11-12 | -$2.42M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $9.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $6.11M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$3.29M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$532.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |